Castle Biosciences Inc (CSTL)
| Market Cap | 1.01B+44.0% |
| Revenue (ttm) | 357.28M |
| Net Income | -19.41M |
| EPS | -0.64 |
| Shares Out | 30.55M |
| PE Ratio | n/a |
| Forward PE | -35.15 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 351,523 |
| Open | 33.15 |
| Previous Close | 33.36 |
| Day's Range | 32.81 - 33.72 |
| 52-Week Range | 17.72 - 44.28 |
| Beta | 0.94 |
| Analysts | Strong Buy |
| Price Target | 45.11(+36.70%) |
| Earnings Date | Nov 2, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About CSTL
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis for patients with invasive cutaneous melanoma; TissueCypher, a risk stratification spatialomics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, and low-grade dysplasia BE; AdvanceAD-Tx, a non-invasive GEP test which is designed to guide systemic treatment selection for patients aged 12 years and older with moderateto-severe AD; DecisionDx-SCC, a GEP test for cutaneous squamous cell carcinoma; and MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions. It also provides DecisionDx-UM, a risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma. The company offers its products to dermatology and gastroenterology markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$CSTL stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of CSTL by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Gilbert Ray CisnerosHouse / D | Purchase$1.00K – $15.00K | Dec 23, 2020 |
| Gilbert CisnerosHouse / D | Purchase$1.00K – $15.00K | Dec 23, 2020 |
| Gilbert Ray CisnerosHouse / D | Purchase$1.00K – $15.00K | Dec 22, 2020 |
Recently reported changes in CSTL holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CSTL's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CSTL Estimated quarterly lobbying spending
Source: U.S. Senate LDA
CSTL Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Non-Dermatologic | $54.84M | 52.96% |
| Dermatologic | $48.70M | 47.04% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New CSTL patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CSTL from public contracts
Source: USAspending.gov
CSTL Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from CSTL’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score